Kelly Smith is the Founder and CEO of V2 Clinical, a next-generation Functional Service Provider (FSP) designed to modernize clinical development for emerging biotech companies. With more than 20 years in biotech operations, clinical strategy, and complex contract negotiation, Kelly helps founders reduce operational friction, protect runway, and accelerate therapies to patients.

He has led clinical operations, negotiated sophisticated site and service agreements, guided early-stage programs through execution, and supported companies as they scale. Recognizing that rigid outsourcing models often slow innovation, he founded V2 Clinical to deliver a sponsor-centric alternative.

Under his leadership, V2 Clinical combines deep operational expertise, FMV-aligned contracting, and AI-driven clinical enablement. The company provides clinical operations and study startup execution, site budget and contract strategy, data management and biostatistics, global privacy and compliance services (GDPR, HIPAA), and AI-powered simulation and feasibility tools that reduce timelines and cost.

Previously President of Virtus Group, where he led boutique consulting services for small- to mid-size life sciences companies, Kelly worked closely with biotech founders and executive teams on operational strategy, contract negotiation, and scalable infrastructure design. He is also a recognized thought leader on biotech funding strategy, the impact of looming patent cliffs, clinical outsourcing models (FSP vs. CRO), and fair market value in research. Through his writing and industry commentary, he brings practical insight into how financial dynamics, diligence standards, and operational design directly influence innovation, execution speed, and long-term value creation in biotech.